Cross-platform Comparisons for Targeted Bisulfite Sequencing of MGISEQ-2000 and NovaSeq6000

Overview

Journal Clin Epigenetics

Publisher Biomed Central

Specialty Genetics

Date 2023 Aug 15

PMID 37582783

Authors

Jin Sun

Mingyang Su

Jianhua Ma

Minjie Xu

Chengcheng Ma

Wei Li

Rui Liu

Qiye He

Zhixi Su

Affiliations

Soon will be listed here.

Abstract

Background: An accurate and reproducible next-generation sequencing platform is essential to identify malignancy-related abnormal DNA methylation changes and translate them into clinical applications including cancer detection, prognosis, and surveillance. However, high-quality DNA methylation sequencing has been challenging because poor sequence diversity of the bisulfite-converted libraries severely impairs sequencing quality and yield. In this study, we tested MGISEQ-2000 Sequencer's capability of DNA methylation sequencing with a published non-invasive pancreatic cancer detection assay, using NovaSeq6000 as the benchmark.

Results: We sequenced a series of synthetic cell-free DNA (cfDNA) samples with different tumor fractions and found MGISEQ-2000 yielded data with similar quality as NovaSeq6000. The methylation levels measured by MGISEQ-2000 demonstrated high consistency with NovaSeq6000. Moreover, MGISEQ-2000 showed a comparable analytic sensitivity with NovaSeq6000, suggesting its potential for clinical detection. As to evaluate the clinical performance of MGISEQ-2000, we sequenced 24 clinical samples and predicted the pathology of the samples with a clinical diagnosis model, PDACatch classifier. The clinical model performance of MGISEQ-2000's data was highly consistent with that of NovaSeq6000's data, with the area under the curve of 1. We also tested the model's robustness with MGISEQ-2000's data when reducing the sequencing depth. The results showed that MGISEQ-2000's data showed matching robustness of the PDACatch classifier with NovaSeq6000's data.

Conclusions: Taken together, MGISEQ-2000 demonstrated similar data quality, consistency of the methylation levels, comparable analytic sensitivity, and matching clinical performance, supporting its application in future non-invasive early cancer detection investigations by detecting distinct methylation patterns of cfDNAs.

Citing Articles

Beyond the base pairs: comparative genome-wide DNA methylation profiling across sequencing technologies.

Liu X, Pang Y, Shan J, Wang Y, Zheng Y, Xue Y Brief Bioinform. 2024; 25(5).

PMID: 39256199 PMC: 11387064. DOI: 10.1093/bib/bbae440.

METTL3 Inhibition Suppresses Cell Growth and Survival in Colorectal Cancer via ASNS Downregulation.

Yu Y, Hai Y, Zhou H, Bao W, Hu X, Gao Y J Cancer. 2024; 15(15):4853-4865.

PMID: 39132158 PMC: 11310885. DOI: 10.7150/jca.96760.

The performance of homopolymer detection using dichromatic and tetrachromatic fluorogenic next-generation sequencing platforms.

Chen H, Wang B, Cai L, Zhang Y, Shu Y, Liu W BMC Genomics. 2024; 25(1):542.

PMID: 38822237 PMC: 11140927. DOI: 10.1186/s12864-024-10474-0.

References

Liang N, Li B, Jia Z, Wang C, Wu P, Zheng T . Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning. Nat Biomed Eng. 2021; 5(6):586-599. DOI: 10.1038/s41551-021-00746-5. View

Jiang P, Chan C, Chan K, Cheng S, Wong J, Wong V . Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A. 2015; 112(11):E1317-25. PMC: 4372002. DOI: 10.1073/pnas.1500076112. View

Underhill H, Kitzman J, Hellwig S, Welker N, Daza R, Baker D . Fragment Length of Circulating Tumor DNA. PLoS Genet. 2016; 12(7):e1006162. PMC: 4948782. DOI: 10.1371/journal.pgen.1006162. View

Fehlmann T, Reinheimer S, Geng C, Su X, Drmanac S, Alexeev A . cPAS-based sequencing on the BGISEQ-500 to explore small non-coding RNAs. Clin Epigenetics. 2016; 8:123. PMC: 5117531. DOI: 10.1186/s13148-016-0287-1. View

Frommer M, McDonald L, Millar D, Collis C, Watt F, GRIGG G . A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A. 1992; 89(5):1827-31. PMC: 48546. DOI: 10.1073/pnas.89.5.1827. View

Mitra A, Skrzypczak M, Ginalski K, Rowicka M . Strategies for achieving high sequencing accuracy for low diversity samples and avoiding sample bleeding using illumina platform. PLoS One. 2015; 10(4):e0120520. PMC: 4393298. DOI: 10.1371/journal.pone.0120520. View

Lee H, Martinez-Agosto J, Rexach J, Fogel B . Next generation sequencing in clinical diagnosis. Lancet Neurol. 2019; 18(5):426. DOI: 10.1016/S1474-4422(19)30110-3. View

Krueger F, Andrews S, Osborne C . Large scale loss of data in low-diversity illumina sequencing libraries can be recovered by deferred cluster calling. PLoS One. 2011; 6(1):e16607. PMC: 3030592. DOI: 10.1371/journal.pone.0016607. View

Hudecova I, Smith C, Hansel-Hertsch R, Chilamakuri C, Morris J, Vijayaraghavan A . Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA. Genome Res. 2021; 32(2):215-227. PMC: 8805718. DOI: 10.1101/gr.275691.121. View

10.

Foox J, Tighe S, Nicolet C, Zook J, Byrska-Bishop M, Clarke W . Performance assessment of DNA sequencing platforms in the ABRF Next-Generation Sequencing Study. Nat Biotechnol. 2021; 39(9):1129-1140. PMC: 8985210. DOI: 10.1038/s41587-021-01049-5. View

11.

Kim H, Jeon S, Chung O, Jun J, Kim H, Blazyte A . Comparative analysis of 7 short-read sequencing platforms using the Korean Reference Genome: MGI and Illumina sequencing benchmark for whole-genome sequencing. Gigascience. 2021; 10(3). PMC: 7953489. DOI: 10.1093/gigascience/giab014. View

12.

Mardis E . A decade's perspective on DNA sequencing technology. Nature. 2011; 470(7333):198-203. DOI: 10.1038/nature09796. View

13.

Chen X, Gole J, Gore A, He Q, Lu M, Min J . Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun. 2020; 11(1):3475. PMC: 7374162. DOI: 10.1038/s41467-020-17316-z. View

14.

Chen J, Li X, Zhong H, Meng Y, Du H . Systematic comparison of germline variant calling pipelines cross multiple next-generation sequencers. Sci Rep. 2019; 9(1):9345. PMC: 6597787. DOI: 10.1038/s41598-019-45835-3. View

15.

Li Q, Zhao X, Zhang W, Wang L, Wang J, Xu D . Reliable multiplex sequencing with rare index mis-assignment on DNB-based NGS platform. BMC Genomics. 2019; 20(1):215. PMC: 6416933. DOI: 10.1186/s12864-019-5569-5. View

16.

. Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2022. Nucleic Acids Res. 2021; 50(D1):D27-D38. PMC: 8728233. DOI: 10.1093/nar/gkab951. View

17.

Sesler C, Grigorenko E . Analytical Validation of qPCR-Based Multivariate Index Assays in a Clinical Laboratory: Practical Challenges and Limitations. J Appl Lab Med. 2021; 3(2):267-281. DOI: 10.1373/jalm.2017.025924. View

18.

Kandimalla R, Xu J, Link A, Matsuyama T, Yamamura K, Parker M . EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers. Clin Cancer Res. 2021; 27(22):6135-6144. PMC: 8595812. DOI: 10.1158/1078-0432.CCR-21-1982. View

19.

Campos-Carrillo A, Weitzel J, Sahoo P, Rockne R, Mokhnatkin J, Murtaza M . Circulating tumor DNA as an early cancer detection tool. Pharmacol Ther. 2019; 207:107458. PMC: 6957244. DOI: 10.1016/j.pharmthera.2019.107458. View

20.

Mouliere F, Chandrananda D, Piskorz A, Moore E, Morris J, Ahlborn L . Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018; 10(466). PMC: 6483061. DOI: 10.1126/scitranslmed.aat4921. View